Gender-specific associations of serum insulin-like growth factor-1 with bone health and fractures in older persons

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 11, 2015, Pages 4272-4281

  Van Varsseveld, N C ^a   Sohl, E ^a   Drent, M L ^a   Lips, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C;

ADULT; AGED; AGING; ARTICLE; ATTENUATION; BONE DENSITY; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FEMALE; FRACTURE; HIGH RISK PATIENT; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SEX DIFFERENCE; SOMATOMEDIN C BLOOD LEVEL; VELOCITY; BLOOD; BONE; FRACTURES, BONE; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; OSTEOPOROSIS; PHYSIOLOGY; SEXUAL DEVELOPMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; BONE AND BONES; BONE DENSITY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; NETHERLANDS; OSTEOPOROSIS; RISK ASSESSMENT; SEX CHARACTERISTICS;

EID: 84958596629     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2549     Document Type: Article

References (43)

1. Melton LJ 3rd. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res. 2003;18:1139-1141.
2. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29:535-559.
3. Ljunghall S, Johansson AG, Burman P, Kämpe O, Lindh E, Karlsson FA.Lowplasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. J Intern Med. 1992;232: 59-64.
4. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19:55-79.
5. Drake WM, Carroll PV, Maher KT, et al. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GHdeficient adolescents at the completion of linear growth. J Clin Endocrinol Metab. 2003;88:1658-1663.
6. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16:63-86.
7. Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol Metab. 1994;78:669-674.
8. Wüster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001;16:398-405.
9. van Bunderen CC, van Varsseveld NC, Erfurth EM, Ket JC, Drent ML. Efficacy and safety of growth hormone treatment in adults with growth hormone deficiency: a systematic review of studies on morbidity. Clin Endocrinol (Oxf). 2014;81:1-14.
10. Elbornsson M, Götherström G, Bosius I, Bengtsson BO, Johannsson G, Svensson J. Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol. 2012;166(5):787-795.
11. Mo D, Fleseriu M, Qi R, et al. Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol. 2015;3(5):331-338.
12. Bartke A. Growth hormone and aging: a challenging controversy. Clin Interv Aging. 2008;3:659-665.
13. Pye SR, Almusalam B, Boonen S, et al. Influence of insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 on bone health: results from the European Male Ageing Study. Calcif Tissue Int. 2011;88:503-510.
14. Langlois JA, Rosen CJ, Visser M, et al. Association between insulinlike growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab. 1998; 83:4257-4262.
15. Barrett-Connor E, Goodman-Gruen D. Gender differences in insulin-like growth factorandbone mineral density association in old age: theRancho Bernardo Study. J Bone Miner Res. 1998;13:1343-1349.
16. Janssen JA, Burger H, Stolk RP, et al. Gender-specific relationship between serum free and total IGF-I and bone mineral density in elderly men and women. Eur J Endocrinol. 1998;138:627-632.
17. O'Connor KG, Tobin JD, Harman SM, et al. Serum levels of insulinlike growth factor-I are related to age and not to body composition in healthy women and men. J Gerontol A Biol Sci Med Sci. 1998; 53:M176-M182.
18. Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab. 1999;84:3626-3635.
19. Collins D, Woods A, Herd R, et al. Insulin-like growth factor-I and bone mineral density. Bone. 1998;23:13-16.
20. Vestergaard P, Hermann AP, Orskov H, Mosekilde L. Effect of sex hormone replacement on the insulin-like growth factor system and bone mineral: a cross-sectional and longitudinal study in 595 perimenopausal women participating in the Danish Osteoporosis Prevention Study. J Clin Endocrinol Metab. 1999;84: 2286-2290.
21. Seck T, Scheidt-Nave C, Leidig-Bruckner G, Ziegler R, Pfeilschifter J. Low serum concentrations of insulin-like growth factor I are associated with femoral bone loss in a population-based sample of postmenopausal women. Clin Endocrinol (Oxf). 2001;55:101-106.
22. Lloyd ME, Hart DJ, Nandra D, et al. Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population: the Chingford study. Ann Rheum Dis. 1996;55:870-874.
23. Wüster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J Intern Med. 1993;234:249-255.
24. Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet. 2000;355:898-899.
25. Kassem M, Brixen K, Blum W, Mosekilde L, Eriksen EF. No evidence for reduced spontaneous or growth-hormone-stimulated serum levels of insulin-like growth factor (IGF)-I, IGF-II or IGF binding protein 3 in women with spinal osteoporosis. Eur J Endocrinol. 1994;131:150-155.
26. Ohlsson C, Mellström D, Carlzon D, et al. Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res. 2011;26:865-872.
27. Muñoz-Torres M, Mezquita-Raya P, Lopez-Rodriguez F, Torres-Vela E, de Dios Luna J, Escobar-Jimenez F. The contribution of IGF-I to skeletal integrity in postmenopausal women. Clin Endocrinol (Oxf). 2001;55:759-766.
28. Boonen S,MohanS, Dequeker J, et al. Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein [BP]-3, and IGFBP-5) in age-related (type II) femoral neck osteoporosis. J Bone Miner Res. 1999;14:2150-2158.
29. Yamaguchi T, Kanatani M, Yamauchi M, et al. Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3,-4, and-5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int. 2006; 78:18-24.
30. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2007;18:1675-1681.
31. HuismanM,Poppelaars J, van der HorstM,et al. Cohort profile: the Longitudinal Aging Study Amsterdam. Int J Epidemiol. 2011;40: 868-876.
32. Graafmans WC, Van Lingen A, Ooms ME, Bezemer PD, Lips P. Ultrasound measurements in the calcaneus: precision and its relation with bone mineral density of the heel, hip, and lumbar spine. Bone. 1996;19:97-100.
33. Stel VS, Smit JH, Pluijm SM, Visser M, Deeg DJ, Lips P. Comparison of the LASA Physical Activity Questionnaire with a 7-day diary and pedometer. J Clin Epidemiol. 2004;57:252-258.
34. Clase CM, St Pierre MW, Churchill DN. Conversion between bromcresol green-and bromcresol purple-measured albumin in renal disease. Nephrol Dial Transplant. 2001;16:1925-1929.
35. Herdzik E, Safranow K, Ciechanowski K. Diagnostic value of fasting capillary glucose, fructosamine and glycosylated haemoglobin in detecting diabetes and other glucose tolerance abnormalities compared to oral glucose tolerance test. Acta Diabetol. 2002;39:15-22.
36. Pfeilschifter J, Scheidt-Nave C, Leidig-Bruckner G, et al. Rela-tionship between circulating insulin-like growth factor components and sex hormones in a population-based sample of 50-to 80-year-old men and women. J Clin Endocrinol Metab. 1996; 81:2534-2540.
37. Kuchuk NO, van Schoor NM, Pluijm SM, Smit JH, de Ronde W, Lips P. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf). 2007;67:295-303.
38. Chandrashekar V, Bartke A. The impact of altered insulin-like growth factor-I secretion on the neuroendocrine and testicular functions. Minerva Ginecol. 2005;57:87-97.
39. Boonen S, Rosen C, Bouillon R, et al. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study. J Clin Endocrinol Metab. 2002;87: 1593-1599.
40. Giovannini S, Marzetti E, Borst SE, Leeuwenburgh C. Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults. Mech Ageing Dev. 2008;129:593-601.
41. Jakobsdóttir S, van Nieuwpoort IC, Schaap LA, van Schoor NM, Lips P, Drent ML. Serum insulin-like growth factor-I and body composition in community dwelling older people. Clin Endocrinol (Oxf). 2010;73:173-180.
42. Schürch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:801-809.
43. Bonjour JP, Kohrt W, Levasseur R, Warren M, Whiting S, Kraenzlin M. Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products. Nutr Res Rev. 2014;27:252-267.